2022
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
Hodak E, Geskin L, Guenova E, Ortiz-Romero P, Willemze R, Zheng J, Cowan R, Foss F, Mangas C, Querfeld C. Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion. American Journal Of Clinical Dermatology 2022, 24: 5-14. PMID: 36399227, PMCID: PMC9673193, DOI: 10.1007/s40257-022-00732-w.Peer-Reviewed Original ResearchConceptsMycosis fungoidesDiagnostic delayPrimary cutaneous T-cell lymphomaCutaneous T-cell lymphomaEarly mycosis fungoidesT-cell lymphomaHeterogeneous clinical presentationInitial clinical appearanceInternational expert panelDermatopathological findingsClinical presentationClinical appearanceMF lesionsClinical signsDifferential diagnosisMF diagnosisCorrect diagnosisUnmet needExpert panel discussionDiagnosisExpert panelFungoidesComplex histologyCliniciansDermatologists
2006
A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides
Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberté RJ, Ryan JL, Zonno K, Rook AH. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. Journal Of The American Academy Of Dermatology 2006, 55: 807-813. PMID: 17052486, DOI: 10.1016/j.jaad.2006.06.038.Peer-Reviewed Original ResearchConceptsSeverity-weighted assessment toolMonths of therapyPartial responseRhIL-12Mycosis fungoidesAdverse eventsInterleukin-12Phase II open-label studyDuration of PROpen-label clinical trialTreatment-related adverse eventsRecombinant human IL-12Recombinant human interleukin-12Early-stage MFIIA mycosis fungoidesRhIL-12 treatmentOpen-label studyAlanine aminotransferase levelsLabel clinical trialInjection site reactionsNatural killer cellsT cell activityEarly mycosis fungoidesT helper cellsHuman IL-12